loading
Lyell Immunopharma Inc stock is traded at $9.20, with a volume of 16,589. It is up +1.20% in the last 24 hours and down -27.43% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$9.15
Open:
$9.31
24h Volume:
16,589
Relative Volume:
0.17
Market Cap:
$159.93M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-11.65
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-1.75%
1M Performance:
-27.43%
6M Performance:
-28.96%
1Y Performance:
-71.42%
1-Day Range:
Value
$9.16
$9.4354
1-Week Range:
Value
$8.96
$9.84
52-Week Range:
Value
$7.65
$38.40

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Name
Lyell Immunopharma Inc
Name
Phone
650 695-0677
Name
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Employee
300
Name
Twitter
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LYEL
Lyell Immunopharma Inc
9.26 159.93M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
466.43 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
549.95 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.23 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
539.28 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.68 28.51B 3.81B -644.79M -669.77M -6.24

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-30-24 Downgrade BofA Securities Buy → Underperform
Jun-27-24 Downgrade H.C. Wainwright Buy → Neutral
Aug-28-23 Downgrade JP Morgan Overweight → Neutral
Nov-14-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-11-22 Downgrade Goldman Buy → Neutral
Oct-17-22 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated BofA Securities Buy
Jul-12-21 Initiated Goldman Buy
Jul-12-21 Initiated JP Morgan Overweight
Jul-12-21 Initiated Morgan Stanley Overweight
View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

pulisher
Jun 17, 2025

Lyell’s lymphoma therapy shows high response rate in trial - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell’s lymphoma therapy shows high response rate in trial By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell Immunopharma Announces Promising CAR T-Cell Trial Data - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell Immunopharma (LYEL) Releases Promising Results from LYL314 Trial | LYEL Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Lyell Immunopharma Announces Positive New Clinical Data - GlobeNewswire

Jun 17, 2025
pulisher
Jun 10, 2025

Lyell Immunopharma (LYEL) Strengthens Leadership Team with Key A - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Lyell Immunopharma (LYEL) Announces Key Executive Appointments | LYEL Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Lyell Immunopharma Expands Board, Appoints New Director - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Lyell Immunopharma Strengthens Leadership: Key Hires from BMS, Amgen Shape CAR T-cell Future - Stock Titan

Jun 09, 2025
pulisher
Jun 08, 2025

Lyell Immunopharma (NASDAQ:LYEL) Raised to Hold at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 04, 2025

From Collapse to Comeback: Lyell Immunopharma’s Stock Surge Signals Turning Point - FXLeaders

Jun 04, 2025
pulisher
Jun 04, 2025

From Collapse to Comeback: Lyell Immunopharma's Stock Surge Signals Turning Point—Cancer Breakthrough? - FXLeaders

Jun 04, 2025
pulisher
Jun 04, 2025

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Lyell Immunopharma Showcases Next-Gen Cancer Therapies at Major Goldman Sachs Healthcare Event - Stock Titan

Jun 04, 2025
pulisher
Jun 02, 2025

Imugene CMO and CEO talk trial momentum and immuno-oncology progress - Proactive Investors

Jun 02, 2025
pulisher
Jun 02, 2025

Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Lyell Immunopharma (LYEL) Trading Resumes with Renewed Focus | L - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | LYEL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Morgan Stanley, Walmart, Pfizer and more: Full list of over 150 American companies laying off employees in June - The Economic Times

Jun 02, 2025
pulisher
Jun 02, 2025

Samsung may incorporate Perplexity's AI tech in its phones - Yahoo News

Jun 02, 2025
pulisher
Jun 02, 2025

UK Government announced funding for NHS hospital maintenance - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

Electricity prices rise in the summer. What can you do? - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

Dai-ichi Life to acquire 15% stake in British insurer M&G - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

Should You Buy AGNC Investment While It's Below $10? - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment - Yahoo

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Enhabit, Inc. (NYSE:EHAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Grows Stock Holdings in LCNB Corp. (NASDAQ:LCNB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Invests $244,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Markel Group Inc. (NYSE:MKL) Stake Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 36,555 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $146,000 Stake in Grab Holdings Limited (NASDAQ:GRAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Tiptree Inc. (NASDAQ:TIPT) Shares Sold by Millennium Management LLC - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Cetera Investment Advisers Grows Stock Holdings in Immersion Co. (NASDAQ:IMMR) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Mondelez sues Aldi over packaging similarities - Yahoo

Jun 02, 2025
pulisher
May 31, 2025

Report: Airbnb brought $900M to Louisiana in 2024 - Yahoo News

May 31, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Takes $162,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 31, 2025
pulisher
May 31, 2025

Lyell Immunopharma (NASDAQ:LYEL) vs. Astellas Pharma (OTCMKTS:ALPMY) Critical Review - Defense World

May 31, 2025
pulisher
May 30, 2025

Lyell Immunopharma (LYEL) Trading Pause Ahead of Important Annou - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Northern Trust Corp Sells 45,853 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 30, 2025
pulisher
May 29, 2025

Imugene appoints Dr John Byon as chief medical officer to lead next phase of clinical development - Proactive Investors

May 29, 2025
pulisher
May 28, 2025

Lyell Immunopharma Announces 1-for-20 Reverse Stock Split - TipRanks

May 28, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Boosts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 25, 2025
pulisher
May 21, 2025

Lyell Immunopharma Stockholders Approve Key Proposals - TipRanks

May 21, 2025
pulisher
May 14, 2025

Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post

May 14, 2025

Lyell Immunopharma Inc Stock (LYEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lyell Immunopharma Inc Stock (LYEL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ramachandra Sumant
Director
Mar 21 '25
Buy
0.58
200,000
115,220
200,000
Klausner Richard
Director
Mar 14 '25
Buy
0.60
158,000
94,942
843,365
Newton Charles W.
Chief Financial Officer
Mar 17 '25
Buy
0.56
200,000
111,620
200,000
Seely Lynn
President and CEO
Mar 14 '25
Buy
0.61
175,000
106,190
712,500
$21.01
price up icon 1.80%
$35.71
price down icon 0.18%
$22.83
price up icon 0.62%
$96.88
price down icon 0.67%
$111.47
price up icon 0.91%
biotechnology ONC
$243.50
price up icon 0.85%
Cap:     |  Volume (24h):